Helmut Butzkueven, Anne-Louise Ponsonby, Mark S Stein, Robyn M Lucas, Deborah Mason, Simon Broadley, Trevor Kilpatrick, Jeannette Lechner-Scott, Michael Barnett, William Carroll, Peter Mitchell, Todd A Hardy, Richard Macdonell, Pamela McCombe, Andrew Lee, Tomas Kalincik, Anneke van der Walt, Chris Lynch, David Abernethy, Ernest Willoughby, Frederik Barkhof, David MacManus, Michael Clarke, Julie Andrew, Julia Morahan, Chao Zhu, Keith Dear, Bruce V Taylor
Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis have been inconclusive. The effects of vitamin D supplementation to prevent multiple sclerosis is unknown. We aimed to test the hypothesis that oral vitamin D3 supplementation in high-risk clinically isolated syndrome (abnormal MRI, at least three T2 brain and/or spinal cord lesions), delays time to conversion to definite multiple sclerosis, that the therapeutic effect is dose-dependent, and that all doses are safe and well tolerated...
April 4, 2024: Brain